23andMe/ME

$0.48

36.13%
-
1D1W1MYTD1YMAX

About 23andMe

23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Ticker

ME

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

CEO

Anne Wojcicki

Employees

769

Headquarters

South san francisco, United States

23andMe Metrics

BasicAdvanced
$193.94M
Market cap
-
P/E ratio
-$1.10
EPS
1.34
Beta
-
Dividend rate
$193.94M
1.33927
$2.26
$0.39
6.58M
2.15
2.042
-63.93%
-92.53%
-81.01%
0.782
0.514
1.146
-19.4%
7.74%
-0.66%

What the Analysts think about 23andMe

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
158.33% upside
High $2.00
Low $0.47
$0.48
Current price
$1.24
Average price target

23andMe Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-621.7% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$44.7M
-10.42%
Net income
$-277.9M
269.55%
Profit margin
-621.7%
312.54%

23andMe Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.29%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.14
-$0.23
-$0.16
-$0.16
-
Expected
-$0.16
-$0.15
-$0.14
-$0.14
-$0.15
Surprise
-11.76%
53.85%
13.88%
14.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for 23andMe stock?

23andMe (ME) has a market cap of $193.94M as of April 18, 2024.

What is the P/E ratio for 23andMe stock?

The price to earnings (P/E) ratio for 23andMe (ME) stock is 0 as of April 18, 2024.

Does 23andMe stock pay dividends?

No, 23andMe (ME) stock does not pay dividends to its shareholders as of April 18, 2024.

When is the next 23andMe dividend payment date?

23andMe (ME) stock does not pay dividends to its shareholders.

What is the beta indicator for 23andMe?

23andMe (ME) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the 23andMe stock price target?

The target price for 23andMe (ME) stock is $1.24, which is 158.33% above the current price of $0.48. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell 23andMe stock

Buy or sell 23andMe stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing